Inquiry Basket
Loading ......
Nivolumab is a fully human IgG4 monoclonal antibody that targets the immune checkpoint programmed death receptor-1 (PD-1), representing a foundational therapeutic agent in modern immuno-oncology. As a cornerstone of cancer immunotherapy, nivolumab has received regulatory approval across multiple tumor types including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and gastric cancer. Unlike traditional cytotoxic chemotherapies that directly kill tumor cells, nivolumab exerts its anti-tumor activity by blocking the PD-1/PD-L1 immune checkpoint axis, thereby restoring the patient's natural tumor-specific T-cell immune response. Despite its profound and durable clinical efficacy in a subset of patients, therapeutic outcomes are significantly influenced by inter-individual variability in drug exposure, target-mediated drug disposition, and the emergence of treatment-induced anti-drug antibodies (ADAs) that can neutralize drug activity, accelerate clearance, and compromise long-term clinical response durability.
Figure 1. Nivolumab ELISA Kits for PD-1 Inhibitor Therapeutic Drug Monitoring.
PD-1 is a member of the CD28 T-cell receptor family expressed primarily on T-cells, B cells, and myeloid cells. Under normal physiological conditions, PD-1 is upregulated following chronic antigen stimulation and produces a state of T-cell exhaustion—a mechanism that prevents overactive immune responses and maintains peripheral tolerance. The ligands for PD-1, PD-L1 and PD-L2, are induced by inflammatory cytokines such as interferon gamma. Tumor cells exploit this pathway by expressing PD-L1 and PD-L2 on their surface; when these ligands bind to PD-1 on tumor-infiltrating T cells, they deliver an inhibitory signal that interrupts the anti-tumor immune response, allowing the tumor to evade immune destruction. Nivolumab blocks this immune checkpoint by competitively occupying the PD-1 receptor, preventing PD-L1 and PD-L2 from engaging PD-1. This blockade reduces inhibitory signaling and restores the patient's tumor-specific T-cell immune response. The combination of nivolumab and ipilimumab—an anti-CTLA-4 antibody—is based on the fact that PD-1 and CTLA-4 checkpoints have nonredundant roles in T-cell modulation, providing a rational basis for dual checkpoint blockade in melanoma, RCC, and NSCLC.
| Key Molecular Targets | Details |
| Programmed Death Receptor-1 (PD-1) | Transmembrane inhibitory co-receptor of the immunoglobulin superfamily; expressed on activated CD4+ and CD8+ T cells, B lymphocytes, natural killer (NK) cells, and tumor-infiltrating myeloid cells following chronic antigen stimulation and inflammatory cytokine exposure. |
| Free Unbound Nivolumab | Circulating intact nivolumab IgG4 molecules not complexed with soluble or membrane-bound PD-1; represents the pharmacologically active drug fraction responsible for checkpoint blockade and anti-tumor immune reactivation. |
| Total Nivolumab (Free + PD-1-Bound + ADA-Bound) | The aggregate pool of all circulating nivolumab species, including free drug, PD-1-complexed drug, and ADA-immunocomplexed drug. Quantified using pan-nivolumab capture reagents for comprehensive exposure assessment. |
Therapeutic drug monitoring for PD-1 inhibitors carries distinctive clinical relevance that diverges from traditional oncology small-molecule or cytotoxic agents. Nivolumab exhibits target-mediated drug disposition (TMDD), where PD-1-expressing T cells act as a pharmacological "sink" that binds circulating drug and reduces measurable free concentrations. High tumor burden and extensive T-cell infiltration can shift the equilibrium toward bound drug, drastically reducing free drug concentrations and limiting anti-tumor activity—a critical analytical gap that measurement of total drug alone cannot resolve. Population pharmacokinetic studies have identified body weight, albumin levels, and baseline PD-1 expression as significant covariates influencing nivolumab clearance and exposure. The wide inter-individual variability in serum drug concentrations—often varying several-fold among patients receiving the same weight-based or flat dose—highlights the potential value of TDM-guided personalized dosing. While routine TDM for checkpoint inhibitors has not yet achieved standard-of-care status in most clinical settings, emerging evidence suggests that maintaining adequate trough concentrations is critical for sustaining PD-1 receptor occupancy and preserving anti-tumor efficacy.
The development of anti-nivolumab ADAs represents a significant clinical challenge that can compromise treatment efficacy. While nivolumab is fully human, its variable region sequences are derived from transgenic mouse systems, retaining foreign epitopes that can trigger an immune response in susceptible patients. Clinical trial data indicate that ADAs develop in a minority of patients, with persistent neutralizing antibodies observed in approximately 5-10% of treated individuals across various tumor types. Risk factors for ADA generation include intermittent dosing schedules, treatment interruptions, low nadir drug levels, and patient-specific HLA-II haplotypes. The most clinically consequential ADAs are those with neutralizing activity—they physically block the interaction between nivolumab and PD-1, abolishing the very mechanism on which therapeutic efficacy depends. In addition, ADA-drug immune complexes are cleared more rapidly by reticuloendothelial system, shortening the antibody's effective half-life and stripping the drug from the PD-1 binding interface. In patients with persistent ADAs, median trough drug levels often fall below therapeutic thresholds, and clinical outcomes may be compromised.
| Kit Name | Primary Applicable Scenarios |
| Nivolumab ELISA Kit | Clinical TDM for PD-1 occupancy assessment; PK/PD modeling of biologically active drug; biosimilar comparability studies; population pharmacokinetic analysis |
| Anti-Nivolumab ELISA Kit | Clinical immunogenicity safety evaluation; ADA incidence endpoint analysis for clinical trials; early identification of patients at risk of persistent antibody positivity; post-marketing pharmacovigilance |
The validated nivolumab ELISA kit duo represents a comprehensive, integrated bioanalytical platform deployed across the full spectrum of clinical drug development, academic translational research, and routine therapeutic drug monitoring workflows. Both kits utilize a robust sandwich ELISA format incorporating high-affinity monoclonal capture and detection antibodies directed against distinct, non-overlapping epitopes on the nivolumab molecule, delivering the sensitivity, specificity, dynamic range, and inter-assay reproducibility demanded by current FDA and EMA bioanalytical method validation guidelines. The ready-to-use, pre-coated 96-well strip microtiter plate format enables batch-wise processing compatible with automated liquid handling platforms, while the short total assay time facilitates high-throughput sample analysis in busy clinical bioanalytical laboratories. Key applications of this integrated platform across the drug development and clinical management continuum include:
Accurate bioanalytical measurement of circulating nivolumab and treatment-induced ADAs constitutes an indispensable pillar of modern immuno-oncology patient care and biopharmaceutical development. The integrated portfolio of Nivolumab ELISA Kit and Anti-Nivolumab ELISA Kit delivers orthogonal, regulatory-compliant immunoassay solutions to resolve key analytical challenges including variable drug target occupancy, clinical immunogenicity risk assessment, and therapeutic drug monitoring. When deployed as a coordinated testing panel, these ELISA platforms enable comprehensive correlation between systemic drug exposure, biologically active free nivolumab levels, and ADA immunogenicity signals, unlocking critical insights into nivolumab pharmacokinetic-pharmacodynamic relationships. For clinical laboratories, contract research organizations, and biotherapeutic developers, this complete nivolumab ELISA assay suite provides a robust standardized analytical toolset to optimize patient therapeutic outcomes, streamline clinical trial bioanalysis, and satisfy global regulatory expectations for therapeutic monoclonal antibody monitoring and immunogenicity safety evaluation.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIAZ0014 | Nivolumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIAZ0015 | Anti-Nivolumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| Nivolumab | CABT-ZB212 | Mouse Anti-Nivolumab monoclonal antibody, clone 9H7H4E9 | IgG1 | ELISA(cap) | Inquiry | |
| Nivolumab | CABT-ZB213 | Mouse Anti-Nivolumab monoclonal antibody, clone 7H6 | IgG1 | ELISA(det) | Inquiry | |
| Nivolumab | CABT-ZB214 | Mouse Anti-Nivolumab monoclonal antibody, clone 7H6 [Biotin] | IgG1 | ELISA(det) | Inquiry | |
| Nivolumab | CABT-ZB215 | Rabbit Anti-Nivolumab monoclonal antibody, clone 44I5 | IgG | ELISA(cap) | Inquiry | |
| Nivolumab | CABT-ZB216 | Rabbit Anti-Nivolumab monoclonal antibody, clone 51G22 | IgG | ELISA(det) | Inquiry | |
| Nivolumab | CABT-ZB217 | Rabbit Anti-Nivolumab monoclonal antibody, clone 51G22 [Biotin] | IgG | ELISA(det) | Inquiry | |
| Nivolumab | CABT-ZB218 | Rabbit Anti-Nivolumab monoclonal antibody, clone 58G7 | IgG | ELISA | Inquiry | |
| Nivolumab | CABT-ZB268 | Rabbit Anti-Nivolumab polyclonal antibody | IgG | ELISA, IA | Inquiry | |
| PDCD1 | CABT-Z633H | Human Anti-Human PD-1 (Nivolumab) Monoclonal Antibody, clone 5C4.B8 [Biosimilar] | Human | IgG4, κ | FA | Inquiry |
Loading ......
